These data showed that high-level HE4-V3 expression is associated with a favorable prognosis in lung adenocarcinoma.

Findings suggest that serum epididymis protein 4 (HE4) is a potential diagnostic and prognostic marker for lung cancer.

High serum HE4 level is associated with pulmonary adenocarcinoma progression.

Serum HE4 may be used as a potential marker to differentiate lung cancer from pulmonary tuberculosis and healthy controls; higher levels of HE4 predict poor prognosis in non-small-cell lung cancer

Data suggest the feasibility of using serum instead of bronchial aspiration fluid (BAF) samples for human epididymis 4 (HE-4) measurements in lung cancer cases.

findings suggested that serum HE4 was a better biomarker in early lung cancer than other frequently-used biomarkers

serum HE4 level was a marker of poor prognosis in lung cancer patients

A panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC.

Higher serum levels of HE4 predict poor prognosis in non-small cell lung carcinoma patients, especially in patients with adenocarcinoma.

serial measurements of serum HE4 levels could provide a valuable method for follow-up monitoring of patients with adenocarcinoma of the lung to detect recurrence

WFDC2 is highly expressed in lung adenocarcinoma tissues with the anti-tumor immunosuppressive effect, which can significantly prolong overall survival of lung adenocarcinoma patients

High serum HE4 levels are associated with lung cancer.

There was no significant difference in the 2 year survival rates of lung cancer patients with high and low HE4 concentrations in pleural fluid (P= 0.882).